These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26944919)

  • 1. Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity.
    Udayakumar TS; Stoyanova R; Shareef MM; Mu Z; Philip S; Burnstein KL; Pollack A
    Mol Cancer Ther; 2016 Jun; 15(6):1353-63. PubMed ID: 26944919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing the mechanism of ethyl acetate extracts of Semen Impatientis against prostate cancer based on network pharmacology and transcriptomics.
    Hu B; Wang C; Wu Y; Han C; Liu J; Chen R; Wang T
    J Ethnopharmacol; 2024 Aug; 330():118228. PubMed ID: 38643863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
    Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
    Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.
    Mohamed AA; Tan SH; Xavier CP; Katta S; Huang W; Ravindranath L; Jamal M; Li H; Srivastava M; Srivatsan ES; Sreenath TL; McLeod DG; Srinivasan A; Petrovics G; Dobi A; Srivastava S
    Mol Cancer Res; 2017 Oct; 15(10):1308-1317. PubMed ID: 28607007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
    Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
    Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
    Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
    Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
    [No Abstract]   [Full Text] [Related]  

  • 7. The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.
    Wang H; Jiang M; Cui H; Chen M; Buttyan R; Hayward SW; Hai T; Wang Z; Yan C
    Mol Cell Biol; 2012 Aug; 32(16):3190-202. PubMed ID: 22665497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
    McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
    J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
    Choi HE; Shin JS; Leem DG; Kim SD; Cho WJ; Lee KT
    Chem Biol Interact; 2016 Dec; 260():196-207. PubMed ID: 27720946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
    Weber H; Ruoff R; Garabedian MJ
    PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
    Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
    IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
    Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
    Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer.
    Singh KB; Ji X; Singh SV
    Mol Cancer Ther; 2018 Oct; 17(10):2079-2090. PubMed ID: 30030299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.